Evidence map›Paper›PMID 29214889›Full record

ArticleTissue engineering. Part A2018

Cell-Seeded Adhesive Biomaterial for Repair of Annulus Fibrosus Defects in Intervertebral Discs.

Michelle A Cruz, Warren W Hom, Tyler J DiStefano, Robert Merrill, Olivia M Torre, Huizi A Lin, Andrew C Hecht, Svenja Illien-Junger, James C Iatridis

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Michelle A Cruz1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
Warren W Hom1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
Tyler J DiStefano1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
Robert Merrill1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
Olivia M Torre1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
Huizi A Lin2 Department of Biomedical Engineering, The City College of New York , New York, New York.
Andrew C Hecht1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
Svenja Illien-Junger1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
James C Iatridis1 Leni & Peter W. May Department of Orthopaedics, Icahn School of Medicine at Mount Sinai , New York, New York.
City College of New York · US

Funding

Model of Human Disc Regeneration in the spectrum of Degenerative Disc DiseaseR01AR057397 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI IATRIDIS, JAMES C. · 2011 to 2021
$5.1M
NIAMS NIH HHS R01 AR057397
6 · The paper itself

Abstract

Defects in the annulus fibrosus (AF) of intervertebral discs allow nucleus pulposus tissue to herniate causing painful disability. Microdiscectomy procedures remove herniated tissue fragments, but unrepaired defects remain allowing reherniation or progressive degeneration. Cell therapies show promise to enhance repair, but methods are undeveloped and carriers are required to prevent cell leakage. To address this challenge, this study developed and evaluated genipin-crosslinked fibrin (FibGen) as an adhesive cell carrier optimized for AF repair that can deliver cells, match AF material properties, and have low risk of extrusion during loading. Part 1 determined that feasibility of bovine AF cells encapsulated in high concentration FibGen (F140G6: 140 mg/mL fibrinogen; 6 mg/mL genipin) for 7 weeks could maintain high viability, but had little proliferation or matrix deposition. Part 2 screened tissue mechanics and in situ failure testing of nine FibGen formulations (fibrin: 35-140 mg/mL; genipin: 1-6 mg/mL). F140G6 formulation matched AF shear and compressive properties and significantly improved failure strength in situ. Formulations with reduced genipin also exhibited satisfactory material properties and failure behaviors warranting further biological screening. Part 3 screened AF cells encapsulated in four FibGen formulations for 1 week and found that reduced genipin concentrations increased cell viability and glycosaminoglycan production. F70G1 (70 mg/mL fibrinogen; 1 mg/mL genipin) demonstrated balanced biological and biomechanical performance warranting further testing. We conclude that FibGen has potential to serve as an adhesive cell carrier to repair AF defects with formulations that can be tuned to enhance biomechanical and biological performance; future studies are required to develop strategies to enhance matrix production.

Indexed as

AnimalsAnnulus FibrosusBiocompatible MaterialsCattleCell ProliferationCells, CulturedCell SurvivalFibrinGlycosaminoglycansHydrogel, Polyethylene Glycol DimethacrylateIntervertebral DiscIridoidsBiocompatible MaterialsFibringenipinGlycosaminoglycansHydrogel, Polyethylene Glycol DimethacrylateIridoidsadhesive biomaterialannulus fibrosus repairfibringenipinintervertebral disc herniationtissue engineering

Identifiers

PMID29214889
PMCPMC5792242
OpenAlexW2773046645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.